BidaskClub upgraded shares of Cardiovascular Systems (NASDAQ:CSII) from a sell rating to a hold rating in a research report released on Wednesday, BidAskClub reports.

Several other equities analysts also recently issued reports on CSII. Needham & Company LLC upped their price objective on shares of Alteryx to $108.00 and gave the company a buy rating in a report on Thursday, May 2nd. Bank of America set a $7.00 price objective on Deutsche Bank and gave the stock a sell rating in a research report on Thursday, April 11th. Zacks Investment Research lowered Genprex from a hold rating to a sell rating in a research report on Thursday, April 18th. Finally, Stifel Nicolaus lowered Tellurian from a buy rating to a hold rating and decreased their target price for the company from $16.00 to $9.00 in a research report on Tuesday, July 16th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of Hold and an average target price of $44.00.

Shares of CSII opened at $45.70 on Wednesday. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of 914.00 and a beta of 1.81. Cardiovascular Systems has a 12-month low of $24.84 and a 12-month high of $49.37. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.25 and a quick ratio of 3.78. The company’s fifty day moving average is $42.93.

Cardiovascular Systems (NASDAQ:CSII) last released its quarterly earnings data on Wednesday, May 1st. The medical device company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.05. The firm had revenue of $63.31 million during the quarter, compared to the consensus estimate of $62.80 million. Cardiovascular Systems had a return on equity of 1.47% and a net margin of 0.84%. As a group, equities analysts forecast that Cardiovascular Systems will post -0.01 EPS for the current year.

Several institutional investors and hedge funds have recently modified their holdings of CSII. Pearl River Capital LLC acquired a new stake in shares of Cardiovascular Systems in the 1st quarter worth $98,000. BerganKDV Wealth Management LLC purchased a new position in shares of Cardiovascular Systems during the 1st quarter worth $155,000. Legal & General Group Plc grew its holdings in shares of Cardiovascular Systems by 21.7% during the 4th quarter. Legal & General Group Plc now owns 6,065 shares of the medical device company’s stock worth $173,000 after purchasing an additional 1,082 shares during the period. LS Investment Advisors LLC purchased a new position in shares of Cardiovascular Systems during the 1st quarter worth $201,000. Finally, Country Club Trust Company n.a. purchased a new position in shares of Cardiovascular Systems during the 1st quarter worth $232,000. 91.99% of the stock is owned by institutional investors and hedge funds.

Cardiovascular Systems Company Profile

Cardiovascular Systems, Inc, a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.

Featured Story: What does the Producer Price Index (PPI) tell investors?

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with's FREE daily email newsletter.